13FPulse
中
NK

NKTR NEKTAR THERAPEUTICS

2026Q2 · CUSIP 640268306 · Sector: Healthcare & Biotech

Piling in

Net holder growth ranks near the top of the market

Funds that own it
236
Institutions that reported holding it to the SEC
Net increase in holders
+30
Last quarter 206 → now 236
How unusual is that
Top 20%
Stronger buying than 89% of US stocks
What the filings say, in one paragraph

236 funds held NKTR at the end of 2026Q2, up 30 from the quarter before. That is stronger buying than 89.4% of US stocks — among the most piled-into names this quarter. On the business itself, revenue over the last 12 months was $55M(YoY -27.2%), return on equity is -17.4%. NKTR has had 5 buying rushes in its history, and the price moved +41.6% on average over the six months after (that is the raw price move, not how much it beat the market by). It sits in the Healthcare & Biotech sector.

How many funds owned it, quarter by quarter

Bars = net change in institutional holders, positive (green) or negative (red). Line = total institutional holders.

2018Q2: holders=1 2018Q3: holders=1 2018Q4: holders=1 2019Q1: holders=1 2019Q3: holders=1 2019Q4: holders=1 2020Q1: holders=1 2020Q2: holders=1 2020Q3: holders=1 2020Q4: holders=1 2021Q1: holders=1 2021Q2: holders=1 2021Q3: holders=1 2021Q4: holders=1 2022Q1: holders=1 2022Q2: holders=1 2022Q3: holders=1 2022Q4: holders=1 2023Q1: holders=1 2025Q2: holders=102 2025Q3: holders=144 2025Q4: holders=173 2026Q1: holders=206 2026Q2: holders=236 -101 -50.5 +0 +50.5 +101 0124248 18Q219Q120Q120Q421Q322Q223Q125Q426Q2 Net change in holders (bars) Total funds holding (line)

What happened after each past buying rush 5 times in its history

Quarter of the rush How unusual then Price, next 3 months Price, next 6 months
2026Q2 Top 20% — —
2026Q1 Top 10% +3.8% —
2025Q4 Top 20% +1.2% -5.9%
2025Q3 Top 10% -27.1% +24.0%
2025Q2 Top 5% +114.5% +106.6%

These are the raw price moves, not how much it beat the market by. Compare them against the market over the same months — in a strong bull market almost everything is up.

Show all the numbers (large funds, value held, options…) ▾
Of them, large funds
118
Change in large funds
+25
Total value they hold
$2.5B
Funds buying for the first time
75
Funds that sold out entirely
45
Price change that quarter
+6.3%
Funds holding puts (bearish)
7
Funds holding calls (bullish)
9

These are for people who want to dig. Skip them if they do not mean anything to you — the three numbers above are enough.

8,697 institutions have filed for this quarter. 13F permits late filing and a small number arrive in the weeks after the deadline, so the holder counts and changes below may tick up.

Fundamentals

PE (TTM)
—
EPS (TTM)
$-6.21
EPS YoY
—
Revenue (TTM)
$0.1B
Revenue YoY
-27.2%
Net margin
-287.8%
ROE
-17.4%
Debt ratio
17.5%
FCF (TTM)
-$234M
Dividend (TTM)
No dividend
Quarterly Revenue & EPS
2024-06-30: EPS -3.76 2024-09-30: EPS -2.66 2024-12-31: EPS -2.07 2025-03-31: EPS -3.62 2025-06-30: EPS -2.95 2025-09-30: EPS -1.87 2025-12-31: EPS -1.29 2026-03-31: EPS -1.82 2026-06-30: EPS -1.23 0B 0.5B 1.1B $B -4.14 -2.07 0.00 2016201720182019202020212022202320242025202606/26 Revenue EPS

Quarterly figures, revenue up to 10 years back; EPS split-adjusted, early quarters hidden when not calibrable

Quarterly free cash flow
-157M400M957M 20162017201820192020202120222023202420252026
Latest quarter $-44M (2026-03-31)

FCF = operating cash flow − capex, computed from SEC XBRL; banks/insurers have no standard cash-flow structure and are hidden

As of 2026-06-30 · SEC filings (XBRL)

Email me the next update

2026 Q3 holdings are due 2026-11-16. We will email you when the refreshed lists are live.